Endocarditis Caused by Staphylococcus aureus with Reduced Susceptibility to Vancomycin

Clinical management of infective endocarditis (IE) is expected to become more difficult with the emergence of Staphylococcus aureus with reduced susceptibility to vancomycin (SARV) in the United States and worldwide. We report the strain characterization and treatment of a patient with SARV IE.

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 38; no. 8; pp. 1188 - 1191
Main Authors Woods, Christopher W., Cheng, Allen C., Fowler, Vance G., Moorefield, Mary, Frederick, Joyce, Sakoulas, George, Meka, Venkata G., Tenover, Fred C., Zwadyk, Peter, Wilson, Kenneth H.
Format Journal Article
LanguageEnglish
Published Chicago, IL The University of Chicago Press 15.04.2004
University of Chicago Press
Subjects
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Bacteremia
Bacterial diseases
Biological and medical sciences
Blood
Brief Report
Cardiology. Vascular system
Endocardial and cardiac valvular diseases
Endocarditis
Endocarditis, Bacterial - drug therapy
Endocarditis, Bacterial - microbiology
Epidemiology
Heart
Human bacterial diseases
Humans
Infections
Infectious diseases
Male
Medical sciences
Microbial Sensitivity Tests
Middle Aged
Preventive medicine
Staphylococcal Infections - drug therapy
Staphylococcal infections, streptococcal infections, pneumococcal infections
Staphylococcus
Staphylococcus aureus
Staphylococcus aureus - drug effects
Treatment Failure
United States
Vancomycin - pharmacology
Vancomycin - therapeutic use
Vancomycin Resistance
Vegetation
United States
North America
America
Human
Peptides
Cardiovascular disease
Vancomycin
Epidemiology
Infection
Characterization
Antibiotic
Clinical management
Treatment
Glycopeptide
Polypeptide
Heart disease
Endocardial disease
Endocarditis
Bacteriosis
Bacteria
Micrococcales
Micrococcaceae
Antibacterial agent
Staphylococcal infection
Staphylococcus aureus
Online AccessGet full text

Cover

More Information
Summary:Clinical management of infective endocarditis (IE) is expected to become more difficult with the emergence of Staphylococcus aureus with reduced susceptibility to vancomycin (SARV) in the United States and worldwide. We report the strain characterization and treatment of a patient with SARV IE.
Bibliography:ark:/67375/HXZ-301X8628-0
istex:2FCFEF6FA5C7F1AF79676F441910FC44058E3577
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Case Study-3
ObjectType-Article-1
ObjectType-Feature-4
ObjectType-Report-2
ISSN:1058-4838
1537-6591
DOI:10.1086/383027